Drug news
Merck pulls plug on Juvisync for Dyslipidaemia
Merck has announced plans to stop selling Juvisync, a combination of Januvia and Zocor (sitagliptin plus simvastatin), for treating Diabetes and Dyslipidaemia. The company has announced that this decision is for business reasons only and is not due to the efficacy or safety profile of Juvisync or the individual components. Distribution of the combination drug in the US and Peurto Rica is set to halt.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.